𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Treatment of refractory acute myeloid leukemia with high-dose cytosine arabinoside and mitoxantrone in combination

✍ Scribed by W. Hiddemann; H. Kreutzmann; W.D. Ludwig; H.C. Aul; R. Donhuijsen-Ant; E. Lengfelder; Th. Büchner

Book ID
113238657
Publisher
Elsevier Science
Year
1986
Tongue
English
Weight
92 KB
Volume
10
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Mitoxantrone and high-dose cytosine arab
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia
✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%

Mitoxantrone and high-dose cytosine arab
Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete

High dose cytosine arabinoside (HDARAC)
High dose cytosine arabinoside (HDARAC) in refractory acute leukemia
✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance